259 related articles for article (PubMed ID: 32276199)
1. Cancer and myeloid clonal evolution in the short telomere syndromes.
Schratz KE; Armanios M
Curr Opin Genet Dev; 2020 Feb; 60():112-118. PubMed ID: 32276199
[TBL] [Abstract][Full Text] [Related]
2. Somatic reversion impacts myelodysplastic syndromes and acute myeloid leukemia evolution in the short telomere disorders.
Schratz KE; Gaysinskaya V; Cosner ZL; DeBoy EA; Xiang Z; Kasch-Semenza L; Florea L; Shah PD; Armanios M
J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34343137
[TBL] [Abstract][Full Text] [Related]
3. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups.
Gadji M; Adebayo Awe J; Rodrigues P; Kumar R; Houston DS; Klewes L; Dièye TN; Rego EM; Passetto RF; de Oliveira FM; Mai S
Clin Cancer Res; 2012 Jun; 18(12):3293-304. PubMed ID: 22539801
[TBL] [Abstract][Full Text] [Related]
4. Cancer spectrum and outcomes in the Mendelian short telomere syndromes.
Schratz KE; Haley L; Danoff SK; Blackford AL; DeZern AE; Gocke CD; Duffield AS; Armanios M
Blood; 2020 May; 135(22):1946-1956. PubMed ID: 32076714
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.
Neukirchen J; Lauseker M; Hildebrandt B; Nolting AC; Kaivers J; Kobbe G; Gattermann N; Haas R; Germing U
Cancer; 2017 Dec; 123(23):4608-4616. PubMed ID: 28746789
[TBL] [Abstract][Full Text] [Related]
6. An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDS.
Kida JI; Tsujioka T; Suemori SI; Okamoto S; Sakakibara K; Takahata T; Yamauchi T; Kitanaka A; Tohyama Y; Tohyama K
Leukemia; 2018 Aug; 32(8):1846-1850. PubMed ID: 29955132
[No Abstract] [Full Text] [Related]
7. Significance of Clonal Mutations in Bone Marrow Failure and Inherited Myelodysplastic Syndrome/Acute Myeloid Leukemia Predisposition Syndromes.
Schaefer EJ; Lindsley RC
Hematol Oncol Clin North Am; 2018 Aug; 32(4):643-655. PubMed ID: 30047417
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activity in myelodysplastic syndromes.
Gürkan E; Tanriverdi K; Başlamişli F
Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
[TBL] [Abstract][Full Text] [Related]
9. Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia.
Dumitriu B; Feng X; Townsley DM; Ueda Y; Yoshizato T; Calado RT; Yang Y; Wakabayashi Y; Kajigaya S; Ogawa S; Zhu J; Young NS
Blood; 2015 Jan; 125(4):706-9. PubMed ID: 25406353
[TBL] [Abstract][Full Text] [Related]
10. Telomeres and telomerase in normal and leukemic hematopoietic cells.
Engelhardt M; Wäsch R; Guo Y
Leuk Res; 2004 Oct; 28(10):1001-4. PubMed ID: 15289009
[TBL] [Abstract][Full Text] [Related]
11. Telomere length is an independent prognostic marker in MDS but not in de novo AML.
Williams J; Heppel NH; Britt-Compton B; Grimstead JW; Jones RE; Tauro S; Bowen DT; Knapper S; Groves M; Hills RK; Pepper C; Baird DM; Fegan C
Br J Haematol; 2017 Jul; 178(2):240-249. PubMed ID: 28486748
[TBL] [Abstract][Full Text] [Related]
12. Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation.
Ohyashiki K; Iwama H; Yahata N; Tauchi T; Kawakubo K; Shimamoto T; Ohyashiki JH
Leuk Lymphoma; 2001 Jul; 42(3):291-9. PubMed ID: 11699393
[TBL] [Abstract][Full Text] [Related]
13. Clonal architecture of secondary acute myeloid leukemia.
Walter MJ; Shen D; Ding L; Shao J; Koboldt DC; Chen K; Larson DE; McLellan MD; Dooling D; Abbott R; Fulton R; Magrini V; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Fan X; Grillot M; Witowski S; Heath S; Frater JL; Eades W; Tomasson M; Westervelt P; DiPersio JF; Link DC; Mardis ER; Ley TJ; Wilson RK; Graubert TA
N Engl J Med; 2012 Mar; 366(12):1090-8. PubMed ID: 22417201
[TBL] [Abstract][Full Text] [Related]
14. What biologic factors predict for transformation to AML?
Bejar R
Best Pract Res Clin Haematol; 2018 Dec; 31(4):341-345. PubMed ID: 30466744
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
16. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
Steensma DP
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation.
Hospital MA; Vey N
Curr Oncol Rep; 2020 Jan; 22(1):4. PubMed ID: 31974774
[TBL] [Abstract][Full Text] [Related]
18. Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita.
Kirschner M; Maurer A; Wlodarski MW; Ventura Ferreira MS; Bouillon AS; Halfmeyer I; Blau W; Kreuter M; Rosewich M; Corbacioglu S; Beck J; Schwarz M; Bittenbring J; Radsak MP; Wilk CM; Koschmieder S; Begemann M; Kurth I; Schemionek M; Brümmendorf TH; Beier F
Leukemia; 2018 Aug; 32(8):1762-1767. PubMed ID: 29749397
[TBL] [Abstract][Full Text] [Related]
19. Clonal evolutions during long-term cultures of bone marrow from de novo acute myeloid leukaemia with trilineage myelodysplasia and with myelodysplastic remission marrow.
Tamura S; Kanamaru A; Takemoto Y; Kakishita E; Nagai K
Br J Haematol; 1993 Jun; 84(2):219-26. PubMed ID: 8398821
[TBL] [Abstract][Full Text] [Related]
20. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
Babushok DV; Bessler M; Olson TS
Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
